PROTEIN TYROSINE PHOSPHATASES IN METABOLIC DISEASES OXIDATION DYSFUNCTION AND...
PROTEIN TYROSINE PHOSPHATASES IN METABOLIC DISEASES OXIDATION DYSFUNCTION AND THERAPEUTIC POTENTIAL
Diabetes mellitus is characterised by hyperglycaemia caused by an absolute or relative insulin deficiency. The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeuti...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2012-33283
LA INHIBICION DE LA PROTEINA TIROSINA FOSFATASA 1B EN EL TRA...
187K€
Cerrado
EUIN2017-85875
P38S EN METABOLISMO, CUATRO QUINASAS QUE COMPARTEN NOMBRE PE...
10K€
Cerrado
PID2021-127741OB-I00
REGULACION DE INTERACCIONES MICRORNA-MRNA Y PROTEINA-PROTEIN...
206K€
Cerrado
BFU2009-07506
PEPCK: IMPLICACIONES EN DIABETES Y HOMEOSTASIS ENERGETICA, Y...
175K€
Cerrado
BES-2013-063982
LA INHIBICION DE LA PROTEINA TIROSINA FOSFATASA 1B EN EL TRA...
84K€
Cerrado
BES-2010-040928
ESTUDIO DE LA SENSIBILIDAD A LA INSULINA EN EL HIGADO MEDIAD...
43K€
Cerrado
Información proyecto METAPTPs
Duración del proyecto: 72 meses
Fecha Inicio: 2019-03-25
Fecha Fin: 2025-03-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Diabetes mellitus is characterised by hyperglycaemia caused by an absolute or relative insulin deficiency. The global prevalence of diabetes has reached more than 410 million individuals, underscoring the need for novel therapeutic strategies targeting the pathology as a multi-organ disease. Protein tyrosine phosphatases (PTPs) constitute a superfamily of enzymes that dephosphorylate tyrosine-phosphorylated proteins and oppose the actions of protein tyrosine kinases. My previous studies and preliminary data suggest that PTPs act as molecular switches for key signalling events in the development of diabetes, i.e. insulin/glucose/cytokine signalling. Dysregulation of these pathways results in metabolic consequences that are cell-specific. Oxidative stress abrogates the nucleophilic properties of the PTP active site and induces conformational changes that inhibit PTP activity and prevent substrate-binding. I have recently developed an innovative proteomic approach to quantify PTP oxidation in vivo and demonstrated that this occurs in liver/pancreas under pathological conditions, including obesity and inflammation. In this proposal, I aim to fully characterise the activity and oxidation status of PTPs in dysfunctional metabolic relevant cells in obesity and diabetes. Importantly, the crucial role of PTPs make them promising candidates for the treatment of metabolic disorders. I hypothesise that specific antioxidants, diets and/or adenovirus will restore PTP function and ameliorate the metabolic deleterious defects in pre-clinical studies. Over the next 5 years, I aim to:
• Identify the major oxidised PTPs in metabolic relevant tissues/cells in both obesity and diabetes.
• Determine the contribution of PTP inactivation in cellular responses to metabolic signalling in human samples.
• Assess the impact of tissue-specific PTP deficiency on the development of obesity and diabetes.
• Test novel therapeutic approaches targeting PTPs to prevent/reverse metabolic disorders.